Eight schizophrenic patients received alprazolam in an open-label protocol. A partial reversal of negative symptoms was noted in six of the eight patients. Also, all eight experienced a decrease in anxiety. Alprazolam in doses of 5 to 7 mg/day yielded steady state plasma levels of 6 to 64 ng/ ml. As the drug was well tolerated at these doses and as negative symptoms of schizophrenia are difficult to treat, a double-blind, controlled trial of alprazolam is underway to test more rigorously these preliminary results.
|Original language||English (US)|
|Number of pages||4|
|Journal||Journal of clinical psychopharmacology|
|State||Published - Dec 1984|
ASJC Scopus subject areas
- Psychiatry and Mental health
- Pharmacology (medical)